Fact Sheet: EtO Sterilization Prevents Infection

February is American Heart Month—a time to spotlight cardiovascular disease and highlight innovations that can improve patient outcomes. For the medtech community, it’s an opportunity to address persistent gaps in care through technology, data, collaboration, and policy advancement. Despite progress in treating heart conditions, sleep disorders—especially sleep apnea—remain a significant and underrecognized contributor to poor cardiovascular outcomes.1 Tackling this issue requires clinical awareness and supportive policies for timely diagnosis, coverage, and care beyond traditional settings.

WASHINGTON—AdvaMed, the Medtech Association, the world’s largest medtech trade association, representing over 650 medical technology innovators, has filed an amicus curiae brief in the Walker v. Becton, Dickinson and Company and C. R. Bard, Inc. case now before the Georgia Court of Appeals, urging the Court to reverse a trial court ruling that allowed unreliable expert testimony on ethylene oxide (EtO) exposure.

WASHINGTON—AdvaMed, the Medtech Association, today announced Melissa Torres is the new Executive Vice President of Technology and Regulatory Affairs. Torres succeeds Janet Trunzo, who retired after 30 distinguished, productive years with AdvaMed. 

WASHINGTON, D.C.—AdvaMed, the world’s largest trade association representing medical technology innovators, announced that its Medical Device Submissions Workshop Series (February 23-27 in Washington, D.C.) has been officially approved for RAC recertification credits by the Regulatory Affairs Professionals Society (RAPS).

After 30 years at AdvaMed, Janet E. Trunzo, Senior Advisor to the President and Senior Executive Vice President of Technology and Regulatory Affairs, will retire on January 31, 2026. Her tenure has fundamentally shaped how medical devices are regulated in the United States and globally, establishing frameworks and standards that continue to govern the field today.

Gain in-depth IDE submission training, meaningful face time with FDA and regulatory leaders, and RAPS accreditation credits at AdvaMed’s IDE Submissions Workshop.

In a new video developed in partnership with Patients Rising, AdvaMed’s Peter Weems, Vice President of Imaging Government Affairs and Policy Strategy, explains why the Health Tech Investment Act is critical to expanding patient access to FDA-authorized AI-enabled medical devices.

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Brian Blaser, president and CEO of QuidelOrtho, will serve as the next chair of the AdvaMedDx Division Board of Directors, succeeding Thierry Bernard, CEO of QIAGEN. AdvaMedDx represents more than 70 manufacturers of the innovative in vitro diagnostic (IVD) tests critical to patient care.